DelveInsight’s “Acute On Chronic Liver Failure (ACLF) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute On Chronic Liver Failure Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Acute On Chronic Liver Failure market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute On Chronic Liver Failure: An Overview
According to AASLD and EASL working group, ACLF is, “Acute deterioration of pre-existing chronic liver disease usually related to a precipitating event and associated with increased mortality at 3-months due to multi-system organ failure”.
On the other hand, the group of experts from APASL defines the ACLF as “Acute liver injury manifesting as jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5 or prothrombin activity of <40%),complicated within 4 weeks by ascites and/or encephalopathy in a patient previously diagnosed or undiagnosed chronic liver diseases.”
Organ failure is a major factor in the clinical course of ACLF. Moreover, the presence of hepatic encephalopathy (HE) within 4 weeks is part of the criteria for defining ACLF. It can be due to hepatotropic or non-hepatotropic agents/causes.
Acute On Chronic Liver Failure Market Key Facts
-
The total population of Acute-on-Chronic Liver Failure (ACLF) in 7MM was found to be 60,521+ in 2017.
-
According to Delveinsight estimates, Germany accounted for the maximum number of cases, which was 17,100+ in 2017.
-
Among the 7MM, the United States had the second-highest population of ACLF, with 12,577+ cases. On the other hand, Italy had the lowest population, with 1,721+ cases in 2017.
-
Japan accounted for 3,720+ cases Acute-on-Chronic Liver Failure (ACLF) in 2017.
Acute On Chronic Liver Failure Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Acute On Chronic Liver Failure market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Acute On Chronic Liver Failure market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Acute On Chronic Liver Failure Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Acute On Chronic Liver Failure (ACLF) Epidemiology Segmentation –
-
Cases of Acute-on-chronic liver failure
-
Cases by Grades
-
Organ failures associated with ACLF
-
Potential precipitating events of ACLF
Acute On Chronic Liver Failure Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute On Chronic Liver Failure market or expected to be launched during the study period. The analysis covers Acute On Chronic Liver Failure market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute On Chronic Liver Failure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
Acute On Chronic Liver Failure Therapeutics Analysis
The dynamic of the Acute On Chronic Liver Failure (ACLF) market is anticipated to change in the coming years owing to the rise in healthcare spending worldwide.
Some of the key companies in the Acute On Chronic Liver Failure (ACLF) Market include:
-
RHEACELL
-
Versantis AG
-
Yaqrit
-
Grifols Therapeutics
-
Promethera Biosciences
And many others.
Acute On Chronic Liver Failure (ACLF) Therapies covered in the report include:
-
PE-A 5%
-
HepaStem
-
APZ2
-
VS-01
-
Dialive
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute On Chronic Liver Failure Competitive Intelligence Analysis
4. Acute On Chronic Liver Failure Market Overview at a Glance
5. Acute On Chronic Liver Failure Disease Background and Overview
6. Acute On Chronic Liver Failure Patient Journey
7. Acute On Chronic Liver Failure Epidemiology and Patient Population
8. Acute On Chronic Liver Failure Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute On Chronic Liver Failure Unmet Needs
10. Key Endpoints of Acute On Chronic Liver Failure Treatment
11. Acute On Chronic Liver Failure Marketed Products
12. Acute On Chronic Liver Failure Emerging Therapies
13. Acute On Chronic Liver Failure Seven Major Market Analysis
14. Attribute Analysis
15. Acute On Chronic Liver Failure Market Outlook (7 major markets)
16. Acute On Chronic Liver Failure Access and Reimbursement Overview
17. KOL Views on the Acute On Chronic Liver Failure Market.
18. Acute On Chronic Liver Failure Market Drivers
19. Acute On Chronic Liver Failure Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Latest Healthcare Report by DelveInsight
Cell And Gene Therapy For Multiple Myeloma Market
“Cell And Gene Therapy For Multiple Myeloma Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/